e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kardigan, Inc. - Common Stock
(NQ:
KARD
)
15.52
+1.66 (+11.98%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kardigan, Inc. - Common Stock
Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results
↗
Today 11:14 EST
Kardigan (NASDAQ:KARD) said its phase 2 trial of investigational drug ataciguat in aortic stenosis is fully enrolled and that it will assess the study’s primary endpoint at 48 weeks, rather than 24...
Via
MarketBeat
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
November 06, 2026
From
Kardigan, Inc.
Via
Business Wire
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
September 30, 2026
From
Kardigan, Inc.
Via
Business Wire
Kardigan to Present at Two September Investor Conferences
September 02, 2026
From
Kardigan, Inc.
Via
Business Wire
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
August 11, 2026
From
Kardigan, Inc.
Via
Business Wire
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
June 22, 2026
From
Kardigan, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.